Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis
Background: Treatment during acute or early human immunodeficiency virus (HIV)-1 infection is associated with immunologic and virologic benefits. Objective: To evaluate darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) efficacy/safety among patients with acute or early HIV-1 infec...
Main Authors: | Keith Dunn, Rachel Rogers, Richard Bruce Simonson, Donghan Luo, Shubin Sheng, Purnima T. Kassam, Sareh Seyedkazemi, Hélène Hardy |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-07-01
|
Series: | HIV Research & Clinical Practice |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/25787489.2021.1915652 |
Similar Items
-
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study
by: Bruce Rashbaum, et al.
Published: (2019-01-01) -
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study
by: Gregory D. Huhn, et al.
Published: (2019-08-01) -
HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study
by: Marianne Harris, et al.
Published: (2017-11-01) -
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study
by: Inés Suárez-García, et al.
Published: (2020-07-01) -
Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection
by: Crutchley RD, et al.
Published: (2016-03-01)